+

US20030119734A1 - Stable formulation of modified GLP-1 - Google Patents

Stable formulation of modified GLP-1 Download PDF

Info

Publication number
US20030119734A1
US20030119734A1 US10/185,923 US18592302A US2003119734A1 US 20030119734 A1 US20030119734 A1 US 20030119734A1 US 18592302 A US18592302 A US 18592302A US 2003119734 A1 US2003119734 A1 US 2003119734A1
Authority
US
United States
Prior art keywords
glp
compound
formulation
concentration
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/185,923
Other languages
English (en)
Inventor
James Flink
Silke Larsen
Simon Jensen
Dorthe Engelund
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27545250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20030119734(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to US10/185,923 priority Critical patent/US20030119734A1/en
Assigned to NOVO NORDISK A/S reassignment NOVO NORDISK A/S ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JENSEN, SIMON BJERREGAARD, LARSEN, SILKE MOLLER, ENGELUND, DORTHE KOT, FLINK, JAMES M.
Publication of US20030119734A1 publication Critical patent/US20030119734A1/en
Priority to US11/786,095 priority patent/US20080167226A1/en
Priority to US12/343,722 priority patent/US20090111752A1/en
Priority to US12/785,861 priority patent/US8846618B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Definitions

  • the present invention relates to pharmaceutical formulations comprising GLP-1 compounds, uses thereof and methods for preparing said formulations.
  • the hormones regulating insulin secretion belong to the so-called enteroinsular axis, designating a group of hormones, released from the gastrointestinal mucosa in response to the presence and absorption of nutrients in the gut, which promote an early and potentiated release of insulin.
  • the enhancing effect on insulin secretion, the so-called incretin effect is probably essential for a normal glucose tolerance.
  • Many of the gastrointestinal hormones, including gastrin and secretin (cholecystokinin is not insulinotropic in man), are insulinotropic, but the only physiologically important ones, those that are responsible for the incretin effect, are the glucose-dependent insulinotropic polypeptide, GIP, and glucagon-like peptide-1(GLP-1).
  • GIP insulin dependent diabetes mellitus
  • NIDDM non insulin-dependent diabetes mellitus
  • GLP-1 a product of the proglucagon
  • GLP-1 is one of the youngest members of the secretin-VIP family of peptides, but is already established as an important gut hormone with regulatory function in glucose metabolism and gastrointestinal secretion and metabolism.
  • the glucagon gene is processed differently in the pancreas and in the intestine.
  • glucagon In the pancreas, the processing leads to the formation and parallel secretion of 1) glucagon itself, occupying positions 33-61 of proglucagon (PG); 2) an N-terminal peptide of 30 amino acids (PG (1-30)) often called glicentin-related pancreatic peptide, GRPP; 3) a hexapeptide corresponding to PG (64-69); 4) and, finally, the so-called major proglucagon fragment (PG (72-158)), in which the two glucagon-like sequences are buried.
  • PG glicentin-related pancreatic peptide
  • PG major proglucagon fragment
  • GLP-1 and analogues of GLP-1 and fragments thereof are potentially useful i.a. in the treatment of type 1 and type 2 diabetes.
  • solubility limitations and the low stability against the actions of endogenous diaminopeptidyl peptidase limits the usefulness of these compounds, and thus there still is a need for improvements in this field.
  • WO 99/43341 are disclosed certain pharmaceutical formulations comprising GLP-1 having a lipophilic substituent. All of the disclosed formulations are maintained at pH 7.4.
  • WO 00/37098 are disclosed shelf-stable formulations comprising GLP-1, a preservative, and a tonicity modifier, at pH 8.2 to 8.8.
  • Human GLP-1 is a 37 amino acid residue peptide originating from preproglucagon which is synthesised i.a. in the L-cells in the distal ileum, in the pancreas and in the brain. Processing of preproglucagon to give GLP-1(7-36)amide, GLP-1(7-37) and GLP-2 occurs mainly in the L-cells. A simple system is used to describe fragments and analogues of this peptide. Thus, for example, Val 8 -GLP-1(7-37) (or Val8GLP-1(7-37)) designates a fragment of GLP-1 formally derived from GLP-1 by deleting the amino acid residues Nos.
  • Lys 34 (N ⁇ -tetradecanoyl)-GLP-1(7-37) designates GLP-1(7-37) wherein the ⁇ -amino group of the Lys residue in position 34 has been tetradecanoylated.
  • amino acid sequence of GLP-1(7-37) is given below, wherein the N-terminal His is no. 7 and the C-terminal Gly is no. 37:
  • modified GLP-1 or analogues thereof when formulated in aqueous solution together with a buffer, are physically stable at high concentrations of the modified GLP-1 or analogues thereof, when kept in the pH range from about 7 to about 10.
  • the present formulations are physically stable within a given shelf life period at the recommended storage temperature (typically 2-3 years at 2-8° C.).
  • the present formulations are physically stable during in-use (typically 1 month at accelerated temperatures e.g. 25° C. or 37° C.).
  • the formulations of the invention are also chemically stable thus rendering them shelf-stable and suitable for invasive (eg.
  • One object of the present invention is to provide a pharmaceutical formulation comprising a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10;
  • Another object of the present invention is to provide a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparing a formulation containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10.
  • the formulation contains a GLP-1 compound in a concentration from 1 mg/ml to 100 mg/ml.
  • the formulation has a pH from 7.5 to 10.
  • the GLP-1 compound is Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37).
  • the invention relates to a pharmaceutical formulation comprising a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10;
  • the invention in another aspect relates to a pharmaceutical formulation comprising a GLP-1compound, and a buffer, wherein said GLP-1 compound is GLP-1 (7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10;
  • the invention relates to a pharmaceutical formulation comprising a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml or above, and wherein said formulation has a pH from 7.0 to 10.
  • the invention relates to a pharmaceutical formulation comprising a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml or above, and wherein said formulation has a pH from 7.0 to 10.
  • the invention relates to a pharmaceutical formulation comprising a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10.
  • the invention relates to a pharmaceutical formulation comprising a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10.
  • the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising prepararing a formulation containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml or above, and wherein said formulation has a pH from 7.0 to 10.
  • the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising prepararing a formulation containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml or above, and wherein said formulation has a pH from 7.0 to 10.
  • the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising prepararing a formulation containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10.
  • the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparing a formulation containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10.
  • the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparing a formulation containing the GLP-1 compound, water, and a buffer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10.
  • the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparing a formulation containing the GLP-1 compound, water, and a buffer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10.
  • the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparing an aqueous solution containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10.
  • the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparing an aqueous solution containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0to 10.
  • the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparing a formulation containing the GLP-1 compound, water, and a buffer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.5 to 10.
  • the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparing a formulation containing the GLP-1 compound, water, and a buffer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.5 to 10.
  • the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparing an aqueous solution containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.5 to 10.
  • the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparing an aqueous solution containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.5 to 10.
  • the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparing a formulation containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10; provided that if an isotonic agent is present and pH is 7.4 then mannitol or NaCl is not the isotonic agent.
  • the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparing a formulation containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10; provided that if an isotonic agent is present and pH is 7.4 then mannitol or NaCl is not the isotonic agent.
  • the pharmaceutical formulation is an aqueous formulation, i.e. a formulation comprising water. Such formulation is typically a solution or a suspension.
  • the pharmaceutical formulation is an aqueous solution.
  • aqueous formulation is defined as a formulation comprising at least 50% w/w water.
  • aqueous solution is defined as a solution comprising at least 50% w/w water
  • aqueous suspension is defined as a suspension comprising at least 50% w/w water.
  • the pharmaceutical formulation is a freeze-dried formulation, whereto the physician or the patient adds the solvent prior to use.
  • the invention relates to a pharmaceutical formulation
  • a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml or above, and wherein said formulation has a pH from 7.0 to 10.
  • the invention relates to a pharmaceutical formulation
  • a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml or above, and wherein said formulation has a pH from 7.0 to 10.
  • the invention relates to a pharmaceutical formulation
  • a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10.
  • the invention relates to a pharmaceutical formulation
  • a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10.
  • the invention relates to a pharmaceutical formulation
  • a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10; provided that if an isotonic agent is present and pH is 7.4 then mannitol or NaCl is not the isotonic agent.
  • the invention relates to a pharmaceutical formulation
  • a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10; provided that if an isotonic agent is present and pH is 7.4 then mannitol or NaCl is not the isotonic agent.
  • the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparation of an aqueous solution containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml or above, and wherein said formulation has a pH from 7.0 to 10.
  • the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparation of an aqueous solution containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml or above, and wherein said formulation has a pH from 7.0 to 10.
  • the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparation of an aqueous solution containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10.
  • the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparation of an aqueous solution containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10.
  • the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparation of an aqueous solution containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10; provided that if an isotonic agent is present and pH is 7.4 then mannitol or NaCl is not the isotonic agent.
  • the invention relates to a method of preparing a physically stable pharmaceutical formulation of a GLP-1 compound wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof, wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, comprising preparation of an aqueous solution containing the GLP-1 compound, and a buffer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10; provided that if an isotonic agent is present and pH is 7.4 then mannitol or NaCl is not the isotonic agent.
  • the present invention relates to a method of reducing blood glucose levels, treating diabetes type I, diabetes type II, obesity, or inhibiting gastric acid secretion, inhibiting apoptosis of ⁇ -cells, or stimulating the proliferation of ⁇ -cells, comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10.
  • the present invention relates to a method of reducing blood glucose levels, treating diabetes type I, diabetes type II, obesity, or inhibiting gastric acid secretion, inhibiting apoptosis of ⁇ -cells, or stimulating the proliferation of ⁇ -cells
  • a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10.
  • the present invention relates to a method of treating gastric ulcers comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10.
  • the present invention relates to a method of treating gastric ulcers comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10.
  • the present invention relates to a method of treating myocardial infarct comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10.
  • the present invention relates to a method of treating myocardial infarct comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10.
  • the present invention relates to a method of treating impaired glucose tolerance (IGT) comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10.
  • ITT impaired glucose tolerance
  • the present invention relates to a method of treating impaired glucose tolerance (IGT) comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10.
  • ITT impaired glucose tolerance
  • the present invention relates to a method of reducing body weight in a subject in need of body weight reduction comprising administering to the subject an effective amount sufficient to cause reduction in body weight for a period of time effective to produce weight loss, said time being at least 4 weeks, of a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10.
  • the present invention relates to a method of reducing body weight in a subject in need of body weight reduction comprising administering to the subject an effective amount sufficient to cause reduction in body weight for a period of time effective to produce weight loss, said time being at least 4 weeks, of a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10.
  • the present invention relates to a method of treating dyslipidemia, stroke, left ventricular hypertrophy, arrhythmia, bacteraemia, septicaemia, irritable bowel disease, functional dyspepsia, comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10.
  • the present invention relates to a method of treating dyslipidemia, stroke, left ventricular hypertrophy, arrhythmia, bacteraemia, septicaemia, irritable bowel disease, functional dyspepsia, comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation comprising an aqueous solution of a GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10.
  • an effective amount is the effective dose to be determined by a qualified practitioner, who may titrate dosages to achieve the desired response. Factors for consideration of dose will include potency, bioavailability, desired pharmacokinetic/pharmacodynamic profiles, condition of treatment (e.g. diabetes, obesity, weight loss, gastric ulcers), patient-related factors (e.g. weight, health, age, etc.), presence of co-administered medications (e.g. insulin), time of administration, or other factors known to a medical practitioner.
  • condition of treatment e.g. diabetes, obesity, weight loss, gastric ulcers
  • patient-related factors e.g. weight, health, age, etc.
  • co-administered medications e.g. insulin
  • time of administration or other factors known to a medical practitioner.
  • the present invention relates to use of a GLP-1 compound for the preparation of a pharmaceutical formulation comprising an aqueous solution of the GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10, for reducing blood glucose levels.
  • the present invention relates to use of a GLP-1 compound for the preparation of a pharmaceutical formulation comprising an aqueous solution of the GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10, for reducing blood glucose levels.
  • the present invention relates to use of a GLP-1 compound for the preparation of a pharmaceutical formulation comprising an aqueous solution of the GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10, for treating diabetes type I.
  • the present invention relates to use of a GLP-1 compound for the preparation of a pharmaceutical formulation comprising an aqueous solution of the GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10, for treating diabetes type I.
  • the present invention relates to use of a GLP-1 compound for the preparation of a pharmaceutical formulation comprising an aqueous solution of the GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10, for treating diabetes type II.
  • the present invention relates to use of a GLP-1 compound for the preparation of a pharmaceutical formulation comprising an aqueous solution of the GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10, for treating diabetes type II.
  • the present invention relates to use of a GLP-1 compound for the preparation of a pharmaceutical formulation comprising an aqueous solution of the GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1 (7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10, for treating obesity.
  • the present invention relates to use of a GLP-1 compound for the preparation of a pharmaceutical formulation comprising an aqueous solution of the GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10, for treating obesity.
  • the present invention relates to use of a GLP-1 compound for the preparation of a pharmaceutical formulation comprising an aqueous solution of the GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10, for reducing body weight, typically for reducing body weight in a type 2 diabetic subject.
  • the present invention relates to use of a GLP-1 compound for the preparation of a pharmaceutical formulation comprising an aqueous solution of the GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10, for reducing body weight, typically for reducing body weight in a type 2 diabetic subject.
  • the present invention relates to use of a GLP-1 compound for the preparation of a pharmaceutical formulation comprising an aqueous solution of the GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10, for treating gastric ulcers.
  • the present invention relates to use of a GLP-1 compound for the preparation of a pharmaceutical formulation comprising an aqueous solution of the GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10, for treating gastric ulcers.
  • the present invention relates to use of a GLP-1 compound for the preparation of a pharmaceutical formulation comprising an aqueous solution of the GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 0.1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10, for inhibition of apoptosis of ⁇ -cells.
  • the present invention relates to use of a GLP-1 compound for the preparation of a pharmaceutical formulation comprising an aqueous solution of the GLP-1 compound, and a buffer, wherein said GLP-1 compound is GLP-1(7-37) or an analogue thereof wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer, wherein said GLP-1 compound is present in a concentration from 1 mg/ml to 100 mg/ml, and wherein said formulation has a pH from 7.0 to 10, for inhibition of apoptosis of ⁇ -cells.
  • treatment is defined as the management and care of a patient, e.g. a mammal, in particular a human, for the purpose of combating the disease, condition, or disorder and includes the administration of a GLP-1 compound to prevent the onset of the symptoms or complications, or alleviating the symptoms or complications, or eliminating the disease, condition, or disorder.
  • Pharmaceutical compositions containing a GLP-1 compound according to the present invention may be administered parenterally to patients in need of such a treatment. Parenteral administration may be performed by subcutaneous, intramuscular or intravenous injection by means of a syringe, optionally a pen-like syringe. Alternatively, parenteral administration can be performed by means of an infusion pump.
  • compositions which may be a solution or suspension for the administration of the GLP-1 compound in the form of a nasal or pulmonal spray are also be adapted to transdermal administration, e.g. from a patch, optionally a iontophoretic patch, or transmucosal, e.g. bucal, administration.
  • a pharmaceutical formulation is found to be physically unstable when it exhibits turbidity.
  • a pharmaceutical formulation of GLP1(7-37) is found to be physically unstable as it turns out to be turbid momentaneously after preparation, whereas the same pharmaceutical formulation comprising a GLP-1 compound, for example Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), is found to be physically stable for more than 90 days at 5° C.
  • Some of the present formulations are physically stable for more than 11 months and for more than 22 months at 5° C.
  • Physical stability of the formulations is evaluated by means of visual inspection and turbidity after storage of the formulation at different temperatures in top filled glass cartridges for various time periods.
  • Visual inspection of the formulations is performed in a sharp focused light with a dark background.
  • the turbidity of the formulation is characterized by a visual score ranking the degree of turbidity from 0 to 3 (a formulation showing no turbidity corresponds to a visual score 0, and a formulation showing visual turbidity in daylight corresponds to visual score 3).
  • a formulation is classified physical unstable with respect to protein aggregation, when it shows visual turbidity in daylight.
  • the pharmaceutical formulation comprising the GLP-1 compound is physically stable for more than 12 weeks and for more than 15 months at 5° C. as measured by visual inspection.
  • the pharmaceutical formulation comprising the GLP-1 compound is physically stable for more than 12 weeks at 25° C. as measured by visual inspection.
  • the pharmaceutical formulation comprising the GLP-1 compound is physically stable for more than 12 weeks at 37° C. as measured by visual inspection.
  • the formulation has a pH in the range from 7.5 to 10. In another embodiment of the invention the formulation has a pH in the range from 7.5 to 9.5. In a further embodiment of the invention the formulation has a pH in the range from 7.0 to 9.5. In a further embodiment of the invention the formulation has a pH in the range from 7.0 to 8.0. In a further embodiment of the invention the formulation has a pH in the range from 7.5 to 8.0. In a further embodiment of the invention the formulation has a pH in the range from 9.0 to 10.
  • the buffer is selected from the group consisting of sodium acetate, sodium carbonate, citrate, glycylglycine, histidine, glycine, lysine, arginin, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium phosphate, and tris(hydroxymethyl)-aminomethan, or mixtures thereof.
  • the buffer is glycylglycine, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium phosphate or mixtures thereof.
  • the GLP-1 compound is present in a concentration from 0.1 mg/ml to 80 mg/ml. In a further embodiment of the invention the GLP-1 compound is present in a concentration from 1 mg/ml to 80 mg/ml. In a further embodiment of the invention the GLP-1 compound is present in a concentration from 0.1 mg/ml to 50 mg/ml. In a further embodiment of the invention the GLP-1 compound is present in a concentration from 1 mg/ml to 50 mg/ml. In a further embodiment of the invention the GLP-1 compound is present in a concentration from 0.1 mg/ml to 20 mg/ml.
  • the GLP-1 compound is present in a concentration from 1 mg/ml to 20 mg/ml. In a further embodiment of the invention the GLP-1 compound is present in a concentration from 0.1 mg/ml to 10 mg/ml. In a further embodiment of the invention the GLP-1 compound is present in a concentration from 1 mg/ml to 10 mg/ml. In a further embodiment of the invention the GLP-1 compound is present in a concentration from 0.1-5 mg/ml. In a further embodiment of the invention the GLP-1 compound is present in a concentration from 1-5 mg/ml. In a further embodiment of the invention the GLP-1 compound is present in a concentration from 0.1-0.5 mg/ml. In a further embodiment of the invention the GLP-1 compound is present in a concentration from 0.6-1 mg/ml. Each one of these specific concentration ranges constitutes an alternative embodiment of the invention.
  • the formulation further comprises a pharmaceutically acceptable preservative.
  • the preservative is selected from the group consisting of phenol, m-cresol, methyl p-hydroxybenzoate, propyl p-hydroxybenzoate, 2-phenoxyethanol, butyl p-hydroxybenzoate, 2-phenylethanol, benzyl alcohol, chlorobutanol, and thiomerosal, or mixtures thereof.
  • the preservative is phenol or m-cresol.
  • the preservative is present in a concentration from 0.1 mg/ml to 20 mg/ml. In a further embodiment of the invention the preservative is present in a concentration from 0.1 mg/ml to 5 mg/ml. In a further embodiment of the invention the preservative is present in a concentration from 5 mg/ml to 10 mg/ml. In a further embodiment of the invention the preservative is present in a concentration from 10 mg/ml to 20 mg/ml. Each one of these specific concentration ranges constitutes an alternative embodiment of the invention.
  • the formulation further comprises an isotonic agent.
  • the isotonic agent is selected from the group consisting of a salt (e.g. sodium chloride), a polyhydric alcohol (e.g. propyleneglycol, xylitol, mannitol, sorbitol or glycerol), a monosaccharide (e.g. glucose or maltose), a disccharide (e.g. sucrose), an amino acid (e.g.
  • the isotonic agent is selected from the group consisting of sodium chloride, glycerol, mannitol, glucose, sucrose, L-glycine, L-histidine, arginine, lysine or mixtures thereof. Each one of these specific isotonic agents constitutes an alternative embodiment of the invention.
  • the isotonic agent is mannitol or glycerol.
  • the isotonic agent is present in a concentration from 1 mg/ml to 50 mg/ml. In a further embodiment of the invention the isotonic agent is present in a concentration from 1 mg/ml to 7 mg/ml. In a further embodiment of the invention the isotonic agent is present in a concentration from 8 mg/ml to 16 mg/ml. In a further embodiment of the invention the isotonic agent is present in a concentration from 17 mg/ml to 50 mg/ml. Each one of these specific concentration ranges constitutes an alternative embodiment of the invention.
  • the formulation further comprises a chelating agent.
  • the chelating agent is selected from salts of ethlenediaminetetraacetic acid (EDTA), citric acid, and aspartic acid, and mixtures thereof. Each one of these specific chelating agents constitutes an alternative embodiment of the invention.
  • the chelating agent is present in a concentration from 0.1 mg/ml to 5 mg/ml. In a further embodiment of the invention the chelating agent is present in a concentration from 0.1 mg/ml to 2 mg/ml. In a further embodiment of the invention the chelating agent is present in a concentration from 2 mg/ml to 5 mg/ml.
  • the formulation further comprises a stabiliser selected from the group of high molecular weight polymers or low molecular compounds.
  • the stabilizer is selected from polyethylene glycol (e.g. PEG 3350), polyvinylalcohol (PVA), polyvinylpyrrolidone, carboxymethylcellulose, different salts (e.g. sodium chloride), L-glycine, L-histidine, imidazole, arginine, lysine, isoleucine, aspartic acid, tryptophan, threonine and mixtures thereof.
  • PEG 3350 polyethylene glycol
  • PVA polyvinylalcohol
  • polyvinylpyrrolidone polyvinylpyrrolidone
  • carboxymethylcellulose different salts (e.g. sodium chloride)
  • the high molecular weight polymer is present in a concentration from 0.1 mg/ml to 50 mg/ml. In a further embodiment of the invention the high molecular weight polymer is present in a concentration from 0.1 mg/ml to 5 mg/ml. In a further embodiment of the invention the high molecular weight polymer is present in a concentration from 5 mg/ml to 10 mg/ml. In a further embodiment of the invention the high molecular weight polymer is present in a concentration from 10 mg/ml to 20 mg/ml. In a further embodiment of the invention the high molecular weight polymer is present in a concentration from 20 mg/ml to 30 mg/ml. In a further embodiment of the invention the high molecular weight polymer is present in a concentration from 30 mg/ml to 50 mg/ml.
  • the low molecular weight compound is present in a concentration from 0.1 mg/ml to 50 mg/ml. In a further embodiment of the invention the low molecular weight compound is present in a concentration from 0.1 mg/ml to 5 mg/ml. In a further embodiment of the invention the low molecular weight compound is present in a concentration from 5 mg/ml to 10 mg/ml. In a further embodiment of the invention the low molecular weight compound is present in a concentration from 10 mg/ml to 20 mg/ml. In a further embodiment of the invention the low molecular weight compound is present in a concentration from 20 mg/ml to 30 mg/ml. In a further embodiment of the invention the low molecular weight compound is present in a concentration from 30 mg/ml to 50 mg/ml.
  • the formulation further comprises a surfactant.
  • the surfactant is selected from a detergent, ethoxylated castor oil, polyglycolyzed glycerides, acetylated monoglycerides, sorbitan fatty acid esters, poloxamers, such as 188 and 407, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene derivatives such as alkylated and alkoxylated derivatives (tweens, e.g.
  • Tween-20, or Tween-80 monoglycerides or ethoxylated derivatives thereof, diglycerides or polyoxyethylene derivatives thereof, glycerol, cholic acid or derivatives thereof, lecithins, alcohols and phospholipids, glycerophospholipids (lecithins, kephalins, phosphatidyl serine), glyceroglycolipids (galactopyransoide), sphingophospholipids (sphingomyelin), and sphingoglycolipids (ceramides, gangliosides), DSS (docusate sodium, CAS registry no [577-11-7]), docusate calcium, CAS registry no [128-49-4]), docusate potassium, CAS registry no [7491-09-0]), SDS (sodium dodecyl sulfate or sodium lauryl sulfate), dipalmitoyl phosphatidic acid, sodium caprylate,
  • N-alkyl-N,N-dimethylammonio-1-propanesulfonates 3-cholamido-1-propyldimethylammonio-1-propanesulfonate
  • dodecylphosphocholine myristoyl lysophosphatidylcholine
  • hen egg lysolecithin cationic surfactants (quarternary ammonium bases) (e.g.
  • acylcarnitines and derivatives N ⁇ -acylated derivatives of lysine, arginine or histidine, or side-chain acylated derivatives of lysine or arginine, N ⁇ -acylated derivatives of dipeptides comprising any combination of lysine, arginine or histidine and a neutral or acidic amino acid, N ⁇ -acylated derivative of a tripeptide comprising any combination of a neutral amino acid and two charged amino acids, or the surfactant may be selected from the group of imidazoline derivatives, or mixtures thereof. Each one of these specific surfactants constitutes an alternative embodiment of the invention.
  • the GLP-1 compound is selected from GLP-1(7-36) or an analogue thereof having a lysine residue wherein a lipophilic substituent optionally via a spacer is attached to the epsilon amino group of said lysine.
  • the GLP-1 compound is selected from a GLP-1(7-36) analogue having one lysine residue wherein one lipophilic substituent optionally via a spacer is attached to the epsilon amino group of said lysine.
  • the GLP-1 compound is selected from Arg26,34,Lys36GLP-1(7-36) having one lysine residue wherein one lipophilic substituent optionally via a spacer is attached to the epsilon amino group of said lysine.
  • the GLP-1 compound is selected from GLP-1(7-37) or an analogue thereof having a lysine residue wherein a lipophilic substituent optionally via a spacer is attached to the epsilon amino group of said lysine.
  • the GLP-1 compound is selected from a GLP-1(7-37) analogue having one lysine residue wherein one lipophilic substituent optionally via a spacer is attached to the epsilon amino group of said lysine.
  • the GLP-1 compound is selected from Arg34GLP-1(7-37), or Arg26GLP-1(7-37) having one lysine residue wherein one lipophilic substituent optionally via a spacer is attached to the epsilon amino group of said lysine.
  • the GLP-1 compound is selected from GLP-1(7-38) or an analogue thereof having a lysine residue wherein a lipophilic substituent optionally via a spacer is attached to the epsilon amino group of said lysine.
  • the GLP-1 compound is selected from a GLP-1(7-38) analogue having one lysine residue wherein one lipophilic substituent optionally via a spacer is attached to the epsilon amino group of said lysine.
  • the GLP-1 compound is selected from Gly8,Arg26,34,Glu37,Lys38GLP-1(7-38) having one lysine residue wherein one lipophilic substituent optionally via a spacer is attached to the epsilon amino group of said lysine.
  • the GLP-1 compound is selected from GLP-1(7-37) or an analogue thereof having one lipophilic substituent optionally attached via a spacer.
  • the lipophilic substituent is attached to any one of the amino acid residues in position 18-37, typically 26-34.
  • the lipophilic substituent is attached to any one of the amino acid residues in position 18-36, typically 26-34.
  • the lipophilic substituent is attached to any one of the amino acid residues in position 18-38, typically 26-34.
  • an analogue is used to designate a peptide wherein one or more amino acid residues of the parent peptide have been substituted by another amino acid residue and/or wherein one or more amino acid residues of the parent peptide have been deleted and/or wherein one or more amino acid residues have been added to the parent peptide. Such addition can take place either at the N-terminal end or at the C-terminal end of the parent peptide or both.
  • GLP-1(7-37) or an analogue thereof comprises GLP-1(7-36), GLP-1(7-37), and GLP-1(7-38), and analogues thereof wherein at least one, preferably at least 3, more preferable at least 5 amino acid residues have been substituted by another amino acid residue.
  • the GLP-1 compound binds to a GLP-1 receptor, preferably with an affinity constant (K D ) or a potency (EC 50 ) of below 1 ⁇ M, e.g. below 100 nM (measured as known in the art, see e.g. WO 98/08871).
  • GLP-1 compound encompasses GLP-1(7-37) and analogues thereof as well as derivatives of any of the foregoing.
  • Derivatives of GLP-1 analogues are GLP-1 analogues which are chemically modified by introducing e.g. ester, alkyl or lipophilic functionalities on one or more amino acid residues of GLP-1 analogues. Methods for identifying GLP-1 compounds are described in WO 93/19175 (Novo Nordisk A/S).
  • lipophilic substituent is characterised by comprising 4-40 carbon atoms and having a solubility in water at 20° C. in the range from about 0.1 mg/100 ml water to about 250 mg/100 ml water, such as in the range from about 0.3 mg/100 ml water to about 75 mg/100 ml water.
  • octanoic acid (C8) has a solubility in water at 20° C. of 68 mg/100 ml
  • decanoic acid (C10) has a solubility in water at 20° C. of 15 mg/100 ml
  • octadecanoic acid (C18) has a solubility in water at 20° C. of 0.3 mg/100 ml.
  • the lipophilic substituent may be attached to an amino group of the GLP-1(7-37) or an analogue thereof by means of a carboxyl group of the lipophilic substituent which forms an amide bond with an amino group of the amino acid residue to which it is attached.
  • the lipophilic substituent may be attached to said amino acid residue in such a way that an amino group of the lipophilic substituent forms an amide bond with a carboxyl group of the amino acid residue.
  • the lipophilic substituent may be linked to the GLP-1(7-37) or an analogue thereof via an ester bond.
  • the ester can be formed either by reaction between a carboxyl group of the GLP-1(7-37) or an analogue thereof and a hydroxyl group of the substituent-to-be or by reaction between a hydroxyl group of the GLP-1(7-37) or an analogue thereof and a carboxyl group of the substituent-to-be.
  • the lipophilic substituent can be an alkyl group which is introduced into a primary amino group of the GLP-1(7-37) or an analogue thereof.
  • the lipophilic substituent may be attached to the GLP-1(7-37) or an analogue thereof by means of a spacer in such a way that a carboxyl group of the spacer forms an amide bond with an amino group of the GLP-1(7-37) or an analogue thereof.
  • a spacer must contain at least two functional groups, one to attach to a functional group of the lipophilic substituent and the other to a functional group of the parent GLP-1(7-37) or an analogue thereof.
  • spacer is used in the present text to designate a bivalent moiety which contain at least two functional groups, one to attach to a functional group of the lipophilic substituent and the other to a functional group of the GLP-1 compound.
  • suitable spacers are succinic acid, lysyl, glutamyl, asparagyl, glycyl, beta-alanyl and gamma-aminobutanoyl, or a dipeptide such as Gly-Lys, each of which constitutes an individual embodiment.
  • one carboxyl group thereof may form an amide bond with an amino group of the amino acid residue, and the other carboxyl group thereof may form an amide bond with an amino group of the lipophilic substituent.
  • the spacer is lysyl, glutamyl, asparagyl, glycyl, beta-alanyl or gamma-aminobutanoyl
  • the carboxyl group thereof may form an amide bond with an amino group of the amino acid residue
  • the amino group thereof may form an amide bond with a carboxyl group of the lipophilic substituent.
  • a further spacer may in some instances be inserted between the ⁇ -amino group of Lys and the lipophilic substituent.
  • a further spacer is succinic acid which forms an amide bond with the ⁇ -amino group of Lys and with an amino group present in the lipophilic substituent.
  • such a further spacer is Glu or Asp which forms an amide bond with the ⁇ -amino group of Lys and another amide bond with a carboxyl group present in the lipophilic substituent, that is, the lipophilic substituent is a N ⁇ -acylated lysine residue.
  • the spacer is an amino acid residue except Cys or Met, or a dipeptide such as Gly-Lys.
  • a dipeptide such as Gly-Lys means any combination of two amino acids except Cys or Met, typically a dipeptide wherein the C-terminal amino acid residue is Lys, His or Trp, typically Lys, and the N-terminal amino acid residue is Ala, Arg, Asp, Asn, Gly, Glu, Gln, lle, Leu, Val, Phe, Pro, Ser, Tyr, Thr, Lys, His and Trp.
  • an amino group of the GLP-1 compound forms an amide bond with a carboxylic group of the amino acid residue or dipeptide spacer
  • an amino group of the amino acid residue or dipeptide spacer forms an amide bond with a carboxyl group of the lipophilic substituent
  • the lipophilic substituent has from 8 to 40 carbon atoms. In a further embodiment of the invention the lipophilic substituent has from 10 to 24 carbon atoms. In a further embodiment of the invention the lipophilic substituent has from 12 to 24 carbon atoms. In a further embodiment of the invention the lipophilic substituent has from 12 to 18 carbon atoms. In a further embodiment of the invention the lipophilic substituent has from 14 to 18 carbon atoms.
  • the spacer is present. In a further embodiment of the invention the spacer is selected from an amino acid. In a further embodiment of the invention, the spacer is an amino acid residue except Cys or Met. In another embodiment, the spacer is a dipeptide such as Gly-Lys. In a further embodiment the spacer is selected from lysyl, glutamyl, asparagyl, glycyl, beta-alanyl and gamma-aminobutanoyl, each of which constitutes an individual embodiment. Typically used spacers are glutamyl, aminobutyroyl, and beta-alanyl (beta-Ala).
  • the spacer is an unbranched alkane ⁇ , ⁇ -dicarboxylic acid group having from 1 to 7 methylene groups, which spacer forms a bridge between an amino group of the parent peptide and an amino group of the lipophilic substituent.
  • the spacer is succinic acid.
  • the lipophilic substituent(s) contain a functional group which can be attached to one of the following functional groups of an amino acid of the parent GLP-1(7-37) or an analogue thereof:
  • the lipophilic substituent is attached to the carboxy group of the R group of any Asp and Glu residue.
  • a lipophilic substituent is attached to the carboxy group attached to the alpha-carbon of the C-terminal amino acid.
  • a lipophilic substituent is attached to the epsilon-amino group of any Lys residue.
  • Each lipophilic substituent contains a functional group which may be attached to a functional group of an amino acid of the parent GLP-1(7-37) or an analogue thereof.
  • a lipophilic substituent may contain a carboxyl group which can be attached to an amino group of the parent GLP-1(7-37) or an analogue thereof by means of an amide bond.
  • the lipophilic substituent comprises a partially or completely hydrogenated cyclopentanophenathrene skeleton.
  • the lipophilic substituent is a straight chain or branched alkyl group.
  • the lipophilic substituent is an acyl group of a straight-chain or branched fatty acid.
  • the lipophilic substituent is an acyl group having the formula CH 3 (CH 2 ) n CO—, wherein n is an integer from 4 to 38. In a further embodiment n is an integer from 12 to 38. In further embodiments the lipophilic substituent is selected from the following individual embodiments CH 3 (CH 2 ) 12 CO—, CH 3 (CH 2 ) 14 CO—, CH 3 (CH 2 ) 16 CO—, CH 3 (CH 2 ) 18 CO—, CH 3 (CH 2 ) 20 CO— and CH 3 (CH 2 ) 22 CO—. In a specific embodiment, the lipophilic substituent is tetradecanoyl. In another specific embodiment, the lipophilic substituent is hexadecanoyl.
  • the lipophilic substituent has a group which is negatively charged such as a carboxylic acid group.
  • the lipophilic substituent may be an acyl group of a straight-chain or branched alkane ⁇ , ⁇ -dicarboxylic acid of the formula HOOC(CH 2 ) m CO—, wherein m is an integer from 4 to 38, preferably an integer from 12 to 38, and most preferably is HOOC(CH 2 ) 14 CO—, HOOC(CH 2 ) 16 CO—, HOOC(CH 2 ) 18 CO—, HOOC(CH 2 ) 20 CO— or HOOC(CH 2 ) 22 CO—.
  • the GLP-1 compound is Arg 26 , 34 ,Lys 36 -(N-epsilon-(gamma-L-glutamyl(N-alfa-hexadecanoyl)))-GLP-1(7-36).
  • the GLP-1 compound is Arg 26 ,Lys 34 -(N-epsilon-(gamma-L-glutamyl(N-alfa-hexadecanoyl)))-GLP-1(7-37).
  • the GLP-1 compound is Gly 8 ,Arg 26,34 , Glu 37 , Lys 38 -(N-epsilon-(gamma-L-glutamyl(N-alfa-hexadecanoyl)))-GLP-1(7-38).
  • the GLP-1 compound is Arg 34 ,Lys 26 -(N-epsilon-(gamma-aminobutyroyl(N-gamma-hexadecanoyl)))-GLP-1(7-37).
  • the GLP-1 compound is Arg 34 ,Lys 26 -(N-epsilon-(beta-alanyl(N-beta-hexadecanoyl)))-GLP-1(7-37).
  • the GLP-1 compound is Arg 34 ,Lys 26 -(N-epsilon-(beta-alanyl-(N-beta-tetradecanoyl)))-GLP-1(7-37).
  • the GLP-1 compound is Arg 34 ,Lys 26 -(N-epsilon-(gamma-aminobutyroyl)-(N-gamma-tetradecanoyl))-GLP-1-(7-37).
  • the GLP-1 compound is Arg 34 ,Lys 26 -(N-epsilon-(beta-alanyl-(N-beta-16-hydroxyhexadecanoyl)))-GLP-1(7-37).
  • the GLP-1 compound is Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37).
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 7.9.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 7.9.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 3 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 7.9.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 5 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 7.9.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 7 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 7.9.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 8.1.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 8.1.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 3 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 8.1.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 5 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 8.1.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 7 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 8.1.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 7.9
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 7.9.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 3 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 7.9.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 5 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 7.9.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 7 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 7.9.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 8.1.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 8.1.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 3 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 8.1.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 5 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 8.1.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 7 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 8.1.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 16.0 mg/ml glycerol, and 5 mg/ml phenol, at pH 7.9.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 16.0 mg/ml glycerol, and 5 mg/ml phenol, at pH 7.9.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 3 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 16.0 mg/ml glycerol, and 5 mg/ml phenol, at pH 7.9.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 16.0 mg/ml glycerol, and 7 mg/ml phenol, at pH 7.9.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 16.0 mg/ml glycerol, and 7 mg/ml phenol, at pH 7.9.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 3 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 16.0 mg/ml glycerol, and 7 mg/ml phenol, at pH 7.9.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 5 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 7.9.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), glycylglycine, 16.0 mg/ml glycerol, and 5 mg/ml phenol, at pH 7.9.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), glycylglycine, 16.0 mg/ml glycerol, and 5 mg/ml phenol, at pH 7.9.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 3 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1 (7-37), glycylglycine, 16.0 mg/ml glycerol, and 5 mg/ml phenol, at pH 7.9.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), glycylglycine, 16.0 mg/ml glycerol, and 7 mg/ml phenol, at pH 7.9.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), glycylglycine, 16.0 mg/ml glycerol, and 7 mg/ml phenol, at pH 7.9.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 3 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), glycylglycine, 16.0 mg/ml glycerol, and 7 mg/ml phenol, at pH 7.9.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate/sodium dihydrogen phosphate, 17.0 mg/ml mannitol, and 18 mg/ml benzylalcohol, at pH 7.0.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate/sodium dihydrogen phosphate, 17.0 mg/ml mannitol, and 18 mg/ml benzylalcohol, at pH 7.0.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 3 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate/sodium dihydrogen phosphate, 17.0 mg/ml mannitol, and 18 mg/ml benzylalcohol, at pH 7.0.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 5 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate/sodium dihydrogen phosphate, 17.0 mg/ml mannitol, and 18 mg/ml benzylalcohol, at pH 7.0.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate/sodium dihydrogen phosphate, 38.5 mg/ml mannitol, and either 3 mg/ml mcresol or 1.5 mg/ml phenol, at pH 7.0.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate/sodium dihydrogen phosphate, 38.5 mg/ml mannitol, and either 3 mg/ml mcresol or 1.5 mg/ml phenol, at pH 7.0.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 3 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate/sodium dihydrogen phosphate, 38.5 mg/ml mannitol, and either 3 mg/ml mcresol or 1.5 mg/ml phenol, at pH 7.0.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 5 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate/sodium dihydrogen phosphate, 38.5 mg/ml mannitol, and either 3 mg/ml mcresol or 1.5 mg/ml phenol, at pH 7.0.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate/sodium dihydrogen phosphate, 17.0 mg/ml mannitol, and 18 mg/ml benzylalcohol, at pH 7.8.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate/sodium dihydrogen phosphate, 17.0 mg/ml mannitol, and 18 mg/ml benzylalcohol, at pH 7.8.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 3 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate/sodium dihydrogen phosphate, 17.0 mg/ml mannitol, and 18 mg/ml benzylalcohol, at pH 7.8.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 5 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate/sodium dihydrogen phosphate, 17.0 mg/ml mannitol, and 18 mg/ml benzylalcohol, at pH 7.8.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), glycine, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 9.4.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), glycine, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 9.4.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 3 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), glycine, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 9.4.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 5 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), glycine, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 9.4.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), glycine, 36.9 mg/ml mannitol, 5 mg/ml phenol, and either 1 mg/ml EDTA or 1.55 mg/ml L-His, at pH 9.4.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), glycine, 36.9 mg/ml mannitol, 5 mg/ml phenol, and 1 mg/ml EDTA/1.55 mg/ml L-His, at pH 9.4.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 16.0 mg/ml glycerol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 7.4.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 16.0 mg/ml glycerol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 7.4.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 5 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 16.0 mg/ml glycerol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 7.4.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 16.0 mg/ml glycerol, 7 mg/ml phenol, and 1.55 mg/ml L-His, at pH 7.4.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 16.0 mg/ml glycerol, 7 mg/ml phenol, and 1.55 mg/ml L-His, at pH 7.4.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 5 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 16.0 mg/ml glycerol, 7 mg/ml phenol, and 1.55 mg/ml L-His, at pH 7.4.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 3 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), glycine, 36.9 mg/ml mannitol, 5 mg/ml phenol, and either 1 mg/ml EDTA or 1.55 mg/ml L-His, at pH 9.4.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 5 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), glycine, 36.9 mg/ml mannitol, 5 mg/ml phenol, and either 1 mg/ml EDTA or 1 .55 mg/ml L-His, at pH 9.4.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), glycine, 36.9 mg/ml mannitol, 5 mg/ml phenol, and either 4 mg/ml Poloxamer 188 or 30 mg/ml PEG 35000, at pH 9.4.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), glycine, 36.9 mg/ml mannitol, 5 mg/ml phenol, and either 4 mg/ml Poloxamer 188 or 30 mg/ml PEG 35000, at pH 9.4.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 3 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), glycine, 36.9 mg/ml mannitol, 5 mg/ml phenol, and either 4 mg/ml Poloxamer 188 or 30 mg/ml PEG 35000, at pH 9.4.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 5 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), glycine, 36.9 mg/ml mannitol, 5 mg/ml phenol, and either 4 mg/ml Poloxamer 188 or 30 mg/ml PEG 35000, at pH 9.4.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 16.0 mg/ml glycerol, and 7 mg/ml phenol, at pH 8.4.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 16.0 mg/ml glycerol, and 7 mg/ml phenol, at pH 8.4.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 3 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 16.0 mg/ml glycerol, and 7 mg/ml phenol, at pH 8.4.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 5 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 16.0 mg/ml glycerol, and 7 mg/ml phenol, at pH 8.4.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 7 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 16.0 mg/ml glycerol, and 7 mg/ml phenol, at pH 8.4.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 8.4.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 8.4.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 3 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1 (7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 8.4.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 5 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 8.4.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 7 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, and 5 mg/ml phenol, at pH 8.4.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 1 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 8.4.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 2 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 8.4.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 3 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 8.4.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 5 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 8.4.
  • the invention relates to a pharmaceutical formulation consisting of an aqueous solution of 7 mg/ml Arg 34 , Lys 26 (N- ⁇ -( ⁇ -Glu(N- ⁇ -hexadecanoyl)))-GLP-1(7-37), disodium hydrogen phosphate, 36.9 mg/ml mannitol, 5 mg/ml phenol, and 1.55 mg/ml L-His, at pH 8.4.
  • the parent peptide, GLP-1(7-37) or analogue thereof can be produced by a method which comprises culturing a host cell containing a DNA sequence encoding the polypeptide and capable of expressing the polypeptide in a suitable nutrient medium under conditions permitting the expression of the peptide, after which the resulting peptide is recovered from the culture.
  • the medium used to culture the cells may be any conventional medium suitable for growing the host cells, such as minimal or complex media containing appropriate supplements. Suitable media are available from commercial suppliers or may be prepared according to published recipes (e.g. in catalogues of the American Type Culture Collection).
  • the peptide produced by the cells may then be recovered from the culture medium by conventional procedures including separating the host cells from the medium by centrifugation or filtration, precipitating the proteinaceous components of the supernatant or filtrate by means of a salt, e.g. ammonium sulphate, purification by a variety of chromatographic procedures, e.g. ion exchange chromatography, gel filtration chromatography, affinity chromatography, or the like, dependent on the type of peptide in question.
  • a salt e.g. ammonium sulphate
  • the DNA sequence encoding the parent peptide may suitably be of genomic or cDNA origin, for instance obtained by preparing a genomic or cDNA library and screening for DNA sequences coding for all or part of the peptide by hybridisation using synthetic oligonucleotide probes in accordance with standard techniques (see, for example, Sambrook, J, Fritsch, EF and Maniatis, T, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York, 1989).
  • the DNA sequence encoding the peptide may also be prepared synthetically by established standard methods, e.g.
  • the DNA sequence may also be prepared by polymerase chain reaction using specific primers, for instance as described in U.S. Pat. No. 4,683,202 or Saiki et al., Science 239 (1988), 487-491.
  • the DNA sequence may be inserted into any vector which may conveniently be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced.
  • the vector may be an autonomously replicating vector, i.e. a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g. a plasmid.
  • the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated.
  • the vector is preferably an expression vector in which the DNA sequence encoding the peptide is operably linked to additional segments required for transcription of the DNA, such as a promoter.
  • the promoter may be any DNA sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell. Examples of suitable promoters for directing the transcription of the DNA encoding the peptide of the invention in a variety of host cells are well known in the art, cf. for instance Sambrook et al., supra.
  • the DNA sequence encoding the peptide may also, if necessary, be operably connected to a suitable terminator, polyadenylation signals, transcriptional enhancer sequences, and translational enhancer sequences.
  • the recombinant vector of the invention may further comprise a DNA sequence enabling the vector to replicate in the host cell in question.
  • the vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host cell or one which confers resistance to a drug, e.g. ampicillin, kanamycin, tetracyclin, chloramphenicol, neomycin, hygromycin or methotrexate.
  • a selectable marker e.g. a gene the product of which complements a defect in the host cell or one which confers resistance to a drug, e.g. ampicillin, kanamycin, tetracyclin, chloramphenicol, neomycin, hygromycin or methotrexate.
  • a secretory signal sequence (also known as a leader sequence, prepro sequence or pre sequence) may be provided in the recombinant vector.
  • the secretory signal sequence is joined to the DNA sequence encoding the peptide in the correct reading frame.
  • Secretory signal sequences are commonly positioned 5′ to the DNA sequence encoding the peptide.
  • the secretory signal sequence may be that normally associated with the peptide or may be from a gene encoding another secreted protein.
  • the host cell into which the DNA sequence or the recombinant vector is introduced may be any cell which is capable of producing the present peptide and includes bacteria, yeast, fungi and higher eukaryotic cells.
  • suitable host cells well known and used in the art are, without limitation, E. coli, Saccharomyces cerevisiae , or mammalian BHK or CHO cell lines.
  • Compound 1 is intended to mean: Arg 34 , Lys 26 (N ⁇ -( ⁇ -Glu(N ⁇ -hexadecanoyl))) GLP-1(7-37).
  • the turbidity of the formulation is characterized by a visual score ranking the degree of turbidity from 0 to 3 (a formulation showing no turbidity corresponds to a visual score 0, and a formulation showing visual turbidity in daylight corresponds to visual score 3).
  • a formulation is classified physical unstable with respect to protein aggregation, when it shows visual turbidity in daylight.
  • the turbidity is also measured in Nephelometric Turbidity Units (NTU) with a nephelometer, which has been calibrated with a Formazin standard.
  • NTU Nephelometric Turbidity Units
  • a formulation with a turbidity>>10 NTU is regarded as physical unstable.
  • Preservative, isotonic agent and buffer were dissolved and pH was adjusted to the specified pH.
  • the Compound 1 or GLP1(7-37) was dissolved under slow stirring.
  • the pH was adjusted to the specified using Sodium Hydroxide and/or Hydrochloric Acid.
  • the formulation was sterilised by filtration through a 0.22 ⁇ m sterile filter. Visual inspection at Turbidity Isotonic 5° C. (visual measurements Compound Amount pH Buffer agent Preservative score) at 5° C.
  • Buffer was dissolved and pH was adjusted to the specified pH.
  • the Compound 1 was dissolved under slow stirring.
  • the pH was adjusted to the specified using Sodium Hydroxide and/or Hydrochloric Acid.
  • the formulation was sterilised by filtration through a 0.22 ⁇ m sterile filter.
  • Preservative and buffer was dissolved and pH was adjusted to the specified pH.
  • the Compound 1 was dissolved under slow stirring.
  • the pH was adjusted to the specified using Sodium Hydroxide and/or Hydrochloric Acid.
  • the formulation was sterilised by filtration through a 0.22 ⁇ m sterile filter.
  • Preservative, isotonic agent and buffer were dissolved and pH was adjusted to the specified pH.
  • the Compound 1 was dissolved under slow stirring.
  • the pH was adjusted to the specified using Sodium Hydroxide and/or Hydrochloric Acid.
  • the formulation was sterilised by filtration through a 0.22 ⁇ m sterile filter.
  • Preservative, isotonic agent, buffer, and further additive(s) selected from chelating agent, stabiliser and surfactant were dissolved and pH was adjusted to the specified pH.
  • the Compound 1 was dissolved under slow stirring.
  • the pH was adjusted to the specified using Sodium Hydroxide and/or Hydrochloric Acid.
  • the formulation was sterilised by filtration through a 0.22 ⁇ m sterile filter.
  • Preservative, isotonic agent and buffer were dissolved and pH adjusted to the specified pH.
  • the Compound was dissolved under slow stirring.
  • the pH was adjusted to the specified using Sodium Hydroxide and/or Hydrochloric Acid.
  • the formulation was sterilised by filtration through a 0.22 ⁇ m sterile filter. The physical stability was followed at 5, 25 and 37° C.
  • the physical stability is evaluated by visual inspection and Turbidity measurements in NTU as described in Example 1.
  • Visual Turbidity Amount of Isotonic inspection measurements Compound 1 PH Buffer agent Preservative Temp. (visual score) (NTU) 3 mg/ml 8.4 Disodium Glycerol Phenol 5° C. 0.5 1.0 hydrogen 16.0 mg/ml 7 mg/ml (12 weeks) (6 weeks) phosphate 3 mg/ml 8.4 Disodium Glycerol Phenol 5° C. 1 0.6 hydrogen 16.0 mg/ml 7 mg/ml (15 months) (15 months) phosphate 3 mg/ml 8.4 Disodium Glycerol Phenol 25° C.
  • the formulation is physically stable after storage at 5° C. for more than 15 months and after storage at, 25 and 37° C. it is physically stable for more than 12 weeks.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
US10/185,923 2001-06-28 2002-06-27 Stable formulation of modified GLP-1 Abandoned US20030119734A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/185,923 US20030119734A1 (en) 2001-06-28 2002-06-27 Stable formulation of modified GLP-1
US11/786,095 US20080167226A1 (en) 2001-06-28 2007-04-11 Stable formulation of modified GLP-1
US12/343,722 US20090111752A1 (en) 2001-06-28 2008-12-24 Stable Formulation of Modified GLP-1
US12/785,861 US8846618B2 (en) 2001-06-28 2010-05-24 Stable formulation of modified GLP-1

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
DKPA200101010 2001-06-28
DKPA200101011 2001-06-28
DKPA200101010 2001-06-28
DKPA200101011 2001-06-28
DKPA200101052 2001-07-04
DKPA200101052 2001-07-04
DKPA200101053 2001-07-04
DKPA200101053 2001-07-04
US30832501P 2001-07-27 2001-07-27
US30829701P 2001-07-27 2001-07-27
DKPA200200092 2002-01-18
DKPA200200092 2002-01-18
DKPA200200093 2002-01-18
DKPA200200093 2002-01-18
US10/185,923 US20030119734A1 (en) 2001-06-28 2002-06-27 Stable formulation of modified GLP-1

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/786,095 Continuation US20080167226A1 (en) 2001-06-28 2007-04-11 Stable formulation of modified GLP-1
US12/343,722 Continuation US20090111752A1 (en) 2001-06-28 2008-12-24 Stable Formulation of Modified GLP-1

Publications (1)

Publication Number Publication Date
US20030119734A1 true US20030119734A1 (en) 2003-06-26

Family

ID=27545250

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/185,923 Abandoned US20030119734A1 (en) 2001-06-28 2002-06-27 Stable formulation of modified GLP-1
US11/786,095 Abandoned US20080167226A1 (en) 2001-06-28 2007-04-11 Stable formulation of modified GLP-1
US12/343,722 Abandoned US20090111752A1 (en) 2001-06-28 2008-12-24 Stable Formulation of Modified GLP-1
US12/785,861 Expired - Lifetime US8846618B2 (en) 2001-06-28 2010-05-24 Stable formulation of modified GLP-1

Family Applications After (3)

Application Number Title Priority Date Filing Date
US11/786,095 Abandoned US20080167226A1 (en) 2001-06-28 2007-04-11 Stable formulation of modified GLP-1
US12/343,722 Abandoned US20090111752A1 (en) 2001-06-28 2008-12-24 Stable Formulation of Modified GLP-1
US12/785,861 Expired - Lifetime US8846618B2 (en) 2001-06-28 2010-05-24 Stable formulation of modified GLP-1

Country Status (10)

Country Link
US (4) US20030119734A1 (fr)
EP (1) EP1412384B1 (fr)
JP (2) JP5562510B2 (fr)
AT (1) ATE382057T1 (fr)
AU (1) AU2002316811A1 (fr)
DE (1) DE60224284T2 (fr)
DK (1) DK1412384T3 (fr)
ES (1) ES2298378T3 (fr)
PT (1) PT1412384E (fr)
WO (1) WO2003002136A2 (fr)

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040037818A1 (en) * 1998-07-30 2004-02-26 Brand Stephen J. Treatment for diabetes
US20040209801A1 (en) * 2002-10-22 2004-10-21 Brand Stephen J. Treatment of diabetes
US20040209816A1 (en) * 1999-01-29 2004-10-21 Indu Parikh Treatment for diabetes
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US20060074025A1 (en) * 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
US20060211616A1 (en) * 2003-08-21 2006-09-21 Novo Nordisk A/S Purification of glucagon-like peptides
US20060234373A1 (en) * 2002-05-24 2006-10-19 Alex Rabinovitch Treatment for diabetes
US20060239924A1 (en) * 2002-02-27 2006-10-26 Bolotin Elijah M Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US20060247167A1 (en) * 2003-09-01 2006-11-02 Novo Nordisk A/S Stable formulations of peptides
US20070010424A1 (en) * 2003-11-20 2007-01-11 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
US20080015263A1 (en) * 2002-02-27 2008-01-17 Bolotin Elijah M Compositions for delivery of therapeutics and other materials
US20080171848A1 (en) * 2004-08-31 2008-07-17 Novo Nordisk A/S Use of Tris(Hydroxymethyl) Aminomethane For the Stabilization of Peptides, Polypeptides and Proteins
US20080234200A1 (en) * 2003-12-26 2008-09-25 Nastech Pharmaceutical Company Inc. Method of treatment of a metabolic disease using intranasal administration of exendin peptide
US20080318837A1 (en) * 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US20080318865A1 (en) * 2003-06-03 2008-12-25 Novo Nordisk A/S Stabilized Pharmaceutical Peptide Compositions
US20080318861A1 (en) * 2005-12-08 2008-12-25 Nastech Pharmaceutical Company Inc. Mucosal Delivery of Stabilized Formulations of Exendin
US20090053169A1 (en) * 2007-08-20 2009-02-26 Pharmain Corporation Oligonucleotide Core Carrier Compositions for Delivery of Nucleic Acid-Containing Therapeutic Agents, Methods of Making and Using the Same
US20090088387A1 (en) * 2007-08-03 2009-04-02 Pharmain Corporation Composition for long-acting peptide analogs
US20090176892A1 (en) * 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
US7560425B2 (en) 2002-06-07 2009-07-14 Waratah Pharmaceuticals Inc. Pharmaceutical composition consisting of rapamycine and gastrin 17(LEU15) and a method for treating diabetes
US20090202494A1 (en) * 2004-01-30 2009-08-13 Antonio Cruz Combined use of glp-1 agonists and gastrin for regulating blood glucose levels
US20100056451A1 (en) * 2003-06-03 2010-03-04 Novo Nordisk A/S Stabilized Pharmaceutical Peptide Compositions
US20100173844A1 (en) * 2004-11-12 2010-07-08 Novo Nordisk A/S Stable Formulations of Peptides
US20100234299A1 (en) * 2001-06-28 2010-09-16 Novo Nordisk A/S Stable formulation of modified glp-1
WO2011123943A1 (fr) 2010-04-09 2011-10-13 Mount Sinai Hospital Méthodes de traitement de troubles du tractus gastro-intestinal au moyen d'un agoniste glp-1
US9670261B2 (en) 2012-12-21 2017-06-06 Sanofi Functionalized exendin-4 derivatives
US9694053B2 (en) 2013-12-13 2017-07-04 Sanofi Dual GLP-1/glucagon receptor agonists
US9737615B2 (en) 2005-12-19 2017-08-22 PharmalN Corporation Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
US9751926B2 (en) 2013-12-13 2017-09-05 Sanofi Dual GLP-1/GIP receptor agonists
US9750788B2 (en) 2013-12-13 2017-09-05 Sanofi Non-acylated exendin-4 peptide analogues
US9758561B2 (en) 2014-04-07 2017-09-12 Sanofi Dual GLP-1/glucagon receptor agonists derived from exendin-4
US9771406B2 (en) 2014-04-07 2017-09-26 Sanofi Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4
US9775904B2 (en) 2014-04-07 2017-10-03 Sanofi Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
US9789165B2 (en) 2013-12-13 2017-10-17 Sanofi Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US9982029B2 (en) 2015-07-10 2018-05-29 Sanofi Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
US10758592B2 (en) 2012-10-09 2020-09-01 Sanofi Exendin-4 derivatives as dual GLP1/glucagon agonists
US10806797B2 (en) 2015-06-05 2020-10-20 Sanofi Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate
CN112912100A (zh) * 2018-10-26 2021-06-04 诺和诺德股份有限公司 稳定的司美鲁肽组合物及其用途
US11318191B2 (en) 2020-02-18 2022-05-03 Novo Nordisk A/S GLP-1 compositions and uses thereof
US11752198B2 (en) 2017-08-24 2023-09-12 Novo Nordisk A/S GLP-1 compositions and uses thereof

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6994857B2 (en) 2000-04-12 2006-02-07 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005003296A2 (fr) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Proteines hybrides d'albumine
EP2277889B1 (fr) 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Protéines chimériques d'albumine et interféron beta
KR20050012224A (ko) 2002-05-21 2005-01-31 다이이찌 산토리 파마 가부시키가이샤 그렐린 함유 의약 조성물
CN1771080B (zh) 2003-04-08 2010-12-15 诺沃挪第克公司 包括至少一个色谱处理步骤的生产治疗用多肽或其前体的方法
WO2004089985A1 (fr) * 2003-04-11 2004-10-21 Novo Nordisk A/S Compositions pharmaceutiques stables
CN102174102A (zh) 2003-05-15 2011-09-07 塔夫茨大学信托人 肽和多肽药物的稳定类似物
WO2004105781A2 (fr) * 2003-06-03 2004-12-09 Novo Nordisk A/S Compositions pharmaceutiques peptidiques stabilisees
JP4463814B2 (ja) 2003-08-05 2010-05-19 ノボ ノルディスク アクティーゼルスカブ 新規のインスリン誘導体
EP1663295A2 (fr) * 2003-09-01 2006-06-07 Novo Nordisk A/S Formulations de peptides stables
WO2005023291A2 (fr) * 2003-09-11 2005-03-17 Novo Nordisk A/S Utilisation d'agonistes de glp-i dans le traitement de patients souffrant de diabete de type i
JP4949838B2 (ja) * 2003-09-19 2012-06-13 ノヴォ ノルディスク アー／エス 新規ｇｌｐ−１誘導体
RU2401276C2 (ru) * 2003-09-19 2010-10-10 Ново Нордиск А/С Производные глюкагон-подобного пептида-1 (glp-1)
EP1667724A2 (fr) 2003-09-19 2006-06-14 Novo Nordisk A/S Nouvelles etiquettes d'affinite pour les proteines plasmiques
ATE498404T1 (de) 2003-12-09 2011-03-15 Novo Nordisk As Regulierung der nahrungspräferenz mit glp-1- agonisten
AR047776A1 (es) * 2003-12-16 2006-02-22 Sod Conseils Rech Applic Composiciones farmaceuticas glp - 1
JP2008501765A (ja) * 2004-06-11 2008-01-24 ノボ　ノルディスク　アクティーゼルスカブ Ｇｌｐ−１アゴニストを用いた薬剤誘発性肥満の中和
WO2006022301A1 (fr) * 2004-08-24 2006-03-02 Daiichi Asubio Pharma Co., Ltd. Préparation liquide d'un peptide physiologiquement actif
WO2006037811A2 (fr) 2004-10-07 2006-04-13 Novo Nordisk A/S Composes d'exendin-4 a action prolongee
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
BRPI0518761A2 (pt) 2004-12-02 2008-12-09 Domantis Ltd fusço de droga, conjugado de droga, Ácido nucleico recombinante, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir uma fusço de droga, composiÇço farmacÊutica, droga, mÉtodo de tratamento e/ou prevenÇço de uma condiÇço em um paciente, mÉtodo de retardo ou prevenÇço de progressço de doenÇa, e, mÉtodo para diminuir a absorÇço de alimentos por um paciente
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
DE602005026998D1 (de) 2005-01-14 2011-04-28 Camurus Ab Somatostatin-analog-formulierungen
ES2458992T3 (es) 2005-01-14 2014-05-07 Camurus Ab Formulaciones de análogos de GnRH
EP1843751B1 (fr) 2005-01-21 2020-09-30 Camurus Ab Compositions lipidiques pharmaceutiques
JP5755398B2 (ja) * 2005-03-18 2015-07-29 ノヴォ ノルディスク アー／エス 伸長されたｇｌｐ−１化合物
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
EP1889618A4 (fr) * 2005-05-27 2010-11-24 Daiichi Sankyo Co Ltd Médicament combiné pour le traitement du diabète
JP5198261B2 (ja) 2005-06-06 2013-05-15 カムルス エービー Ｇｌｐ−１類似体製剤
ES2336575T3 (es) 2005-09-22 2010-04-14 Biocompatibles Uk Limited Polipeptidos de fusion glp-1 (peptido-1 similar al glucagon) con resistencia aumentada a la peptidasa.
ES2371361T3 (es) 2005-12-28 2011-12-30 Novo Nordisk A/S Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
DE602006009631D1 (de) 2006-05-10 2009-11-19 Biocompatibles Uk Ltd GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
EP2167032B1 (fr) 2007-06-13 2019-08-07 Novo Nordisk A/S Formule pharmaceutique contenant d'un dérivé de l'insuline
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
WO2009121804A1 (fr) 2008-03-31 2009-10-08 Glaxo Group Limited Fusions et conjugués médicamenteux
WO2010015668A1 (fr) 2008-08-06 2010-02-11 Novo Nordisk A/S Protéines conjuguées à efficacité in vivo prolongée
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
EP2163243A1 (fr) * 2008-09-12 2010-03-17 Biocompatibles UK Limited Traitement de l'infarctus du myocarde (AMI) utilisant des cellules encapsulées codant et sécrétant des peptides GLP-1 ou analogues associés
CN102202683A (zh) 2008-10-30 2011-09-28 诺沃-诺迪斯克有限公司 用少于每日一次的注射频率注射胰岛素来治疗糖尿病
EP2364326B1 (fr) 2008-12-05 2018-07-04 Glaxo Group Limited Procédés de sélection de polypeptides résistants aux protéases
WO2010084173A1 (fr) 2009-01-22 2010-07-29 Novo Nordisk Health Care Ag Composés stables d'hormone de croissance
TW201100104A (en) 2009-03-27 2011-01-01 Glaxo Group Ltd Drug fusions and conjugates
CN105963710A (zh) 2009-08-06 2016-09-28 诺沃—诺迪斯克保健股份有限公司 具有延长的体内功效的生长激素
CA2774552A1 (fr) 2009-09-30 2011-04-07 Glaxo Group Limited Fusions de medicaments et conjugues presentant une demi-vie prolongee
JP5980689B2 (ja) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
CN118767116A (zh) 2010-01-22 2024-10-15 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
WO2012136792A2 (fr) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions de cck
WO2012136790A1 (fr) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprenant des protéines de fusion ou des conjugués ayant une demi-vie améliorée
US20150038417A1 (en) 2011-12-09 2015-02-05 Novo Nordisk A/S GLP-1 Agonists
KR102139080B1 (ko) 2012-05-25 2020-07-29 카무러스 에이비 소마토스타틴 수용체 작용제 제형
PT2866825T (pt) 2012-07-01 2020-07-15 Novo Nordisk As Uso de péptidos glp-1 de longa ação
CN103893744B (zh) * 2012-12-24 2017-12-19 杭州九源基因工程有限公司 一种治疗糖尿病的药物制剂及其制备方法
CN105120887A (zh) 2013-04-05 2015-12-02 诺和诺德保健股份有限公司 生长激素化合物制剂
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
CN103405753B (zh) * 2013-08-13 2016-05-11 上海仁会生物制药股份有限公司 稳定的促胰岛素分泌肽水针药物组合物
SI3139948T1 (sl) * 2014-05-07 2020-07-31 Novo Nordisk A/S Zdravljenje diabetesa tipa 1 z uporabo GLP-1 in anti-IL-21
WO2016038521A1 (fr) * 2014-09-08 2016-03-17 Sun Pharmaceutical Industries Limited Compositions pharmaceutiques de liraglutide
CN104800572A (zh) * 2015-04-20 2015-07-29 陈兴田 一种治疗伴抑郁焦虑状态的功能性消化不良的中药制剂
WO2016180353A1 (fr) * 2015-05-13 2016-11-17 杭州九源基因工程有限公司 Formulation pharmaceutique comprenant un analogue du glp-1 et son procédé de préparation
JP2019506440A (ja) * 2016-03-01 2019-03-07 深▲せん▼翰宇薬業股▲ふん▼有限公司Ｈｙｂｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． 医薬組成物及びその製造方法
WO2018057977A1 (fr) 2016-09-23 2018-03-29 Delpor, Inc. Compositions stables pour composés mimétiques de l'incrétine
WO2019060783A1 (fr) 2017-09-21 2019-03-28 EMULATE, Inc. Succédané de fluide réologiquement biomimétique
WO2019072941A1 (fr) 2017-10-12 2019-04-18 Novo Nordisk A/S Sémaglutide en thérapie médicale
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
EP3897570A1 (fr) 2018-12-19 2021-10-27 KRKA, d.d., Novo mesto Composition pharmaceutique comprenant un analogue de glp -1
WO2020208541A1 (fr) 2019-04-08 2020-10-15 Enzene Biosciences Limited Composition comprenant un analogue de glp-1
US20220372072A1 (en) * 2019-09-19 2022-11-24 Dr. Reddy's Laboratories Limited Improved purification processes for liraglutide
GB201917723D0 (en) * 2019-12-04 2020-01-15 Nv Rose Llc Stable liquid formulations of glucagon-like peptide 1 or analogues thereof
WO2021123228A1 (fr) 2019-12-18 2021-06-24 Krka, D.D., Novo Mesto Composition pharmaceutique comprenant un analogue de glp-1
AU2022263996A1 (en) 2021-04-27 2023-11-02 Aardvark Therapeutics, Inc. Combination of bitter receptor agonist and gut-signaling compound
CN113249288B9 (zh) * 2021-07-13 2021-11-09 奥锐特药业(天津)有限公司 一种表达glp-1类似物的重组菌及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652216A (en) * 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
US5869602A (en) * 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6380357B2 (en) * 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
US6384016B1 (en) * 1998-03-13 2002-05-07 Novo Nordisk A/S Stabilized aqueous peptide solutions
US20030220255A1 (en) * 2002-04-04 2003-11-27 Knudsen Liselotte Bjerre GLP-1 agonist and cardiovascular complications

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4483849A (en) 1983-01-07 1984-11-20 Carter William A Stabilization and purification of interferon with propylene glycol, resulting in a non-toxic product
US4468346A (en) 1983-10-27 1984-08-28 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies to porcine immunoglobulins
WO1988008673A1 (fr) 1987-05-14 1988-11-17 Commonwealth Scientific And Industrial Research Or Fractions proteiques de petit lait
EP0422124A4 (en) 1988-06-27 1991-10-16 Genex Corporation Thermal release of recombinant protein into culture media
DE69013471T2 (de) 1989-12-05 1995-03-30 Merck & Co Inc Methode zur Stabilisierung von rekombinanten Hepatitis-B-Virus-Oberflächenproteinen aus Hefe.
DE4002066A1 (de) 1990-01-25 1991-08-01 Basf Ag Verfahren zur abtrennung von riboflavin aus fermentationssuspensionen
US5272135A (en) 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
SE9101381D0 (sv) 1991-05-07 1991-05-07 Tomas Moks Peptide hormone solution
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
DK36492D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
WO1993023010A1 (fr) 1992-05-13 1993-11-25 Sandoz Ltd. Compositions ophtalmiques contenant une cyclosporine
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
WO1995005848A1 (fr) 1993-08-24 1995-03-02 Novo Nordisk A/S Peptide-1 du type glucagon a action prolongee
GB9320782D0 (en) 1993-10-08 1993-12-01 Univ Leeds Innovations Ltd Stabilising of proteins on solution
ES2141849T3 (es) 1993-11-19 2000-04-01 Searle & Co Composicion transdermica de n-(n-(5-(4-(aminoiminometil)fenil)-1-oxopentil)-l-alfa-aspartil)-l-fenilalanina o sus esteres y sus sales farmaceuticamente aceptables.
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
WO1995022560A1 (fr) 1994-02-22 1995-08-24 The Syntex-Synergen Neuroscience Joint Venture Formulations pharmaceutiques comprenant un facteur neurotrophique ciliaire
EP0699687B1 (fr) 1994-08-31 2004-01-28 Mitsubishi Pharma Corporation Procédé de purification du sérum albumine recombiné humaine
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
WO1996020005A1 (fr) * 1994-12-23 1996-07-04 Novo Nordisk A/S Compositions a base de glp-1 et a action prolongee
AU695129B2 (en) 1995-02-06 1998-08-06 Genetics Institute, Llc Formulations for IL-12
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
EP0828753B1 (fr) 1995-06-02 2003-03-26 Novozymes A/S Traitement d'une solution proteique avec un compose d'al/fe, suivi d'une concentration membranaire
US5631347A (en) 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
AU737664B2 (en) 1996-07-03 2001-08-30 Alza Corporation Non-aqueous protic peptide formulations
JPH10101696A (ja) 1996-08-08 1998-04-21 Shinotesuto:Kk 形質転換体にて発現される蛋白質に含まれる夾雑物質の除去方法及び精製蛋白質
PT944648E (pt) * 1996-08-30 2007-06-26 Novo Nordisk As Derivados do glp-1.
CA2278199A1 (fr) 1997-01-20 1998-07-23 Japan Energy Corporation Procede de stabilisation de peptides et compositions medicinales lyophilisees comprenant des peptides obtenus par ce procede
CA2236519C (fr) 1997-05-02 2011-09-13 1149336 Ontario Inc. Methodes pour ameliorer le fonctionnement du gros intestin
PE79099A1 (es) 1997-06-13 1999-08-24 Lilly Co Eli Formulaciones de insulina estables
EP1036561A1 (fr) 1997-10-01 2000-09-20 Flemington Pharmaceutical Corporation Vaporisateur buccal non polaire
ATE237636T1 (de) 1997-10-24 2003-05-15 Genentech Inc Reinigung von molekülen
JP2001525371A (ja) 1997-12-05 2001-12-11 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１製剤
DE29721752U1 (de) 1997-12-09 1998-02-12 Siemens AG, 80333 München Crimpkontakt für Stecksysteme
EP1061946B1 (fr) * 1998-02-27 2004-04-28 Novo Nordisk A/S Derives de glp-1 avec une teneur de structures en helices superieure a 25 %, formant des agregats de type micellaire partiellement structures
EP1062240B1 (fr) 1998-02-27 2010-04-28 Novo Nordisk A/S Derives de glp-1 modifies a l'extremite n-terminale
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
ATE466027T1 (de) * 1998-02-27 2010-05-15 Novo Nordisk As Abkömmlinge von glp-1 analogen
AU3772199A (en) 1998-05-01 1999-11-23 University Of Tennessee Research Corporation, The Flow cytometric characterization of amyloid fibrils
JP2002524514A (ja) 1998-09-17 2002-08-06 イーライ・リリー・アンド・カンパニー タンパク質製剤
DE69928006T2 (de) * 1998-12-22 2006-07-13 Eli Lilly And Co., Indianapolis Lagerstabile flüssige zusammensetzungen von glucagon-ähnlichem peptid-1
DK1140145T4 (da) 1999-01-14 2019-07-22 Amylin Pharmaceuticals Llc Hidtil ukendte exendinagonistformuleringer og fremgangsmåder til indgivelse deraf
US6444788B1 (en) 1999-03-15 2002-09-03 Novo Nordisk A/S Ion exchange chromatography of GLP-1, analogs and derivatives thereof
IL144989A0 (en) * 1999-03-17 2002-06-30 Novo Nordisk As Method for acylating peptides and novel acylating agents
JP2003503356A (ja) 1999-06-25 2003-01-28 メドトロニック ミニメド インコーポレイテッド 多剤糖尿病治療
EP1076066A1 (fr) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides abaissant le taux de glucose sanguin
US6569832B1 (en) 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
EP1242121B1 (fr) 1999-12-16 2005-02-09 Eli Lilly And Company Compositions polypeptidiques presentant une stabilite amelioree
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
WO2001051071A2 (fr) 2000-01-11 2001-07-19 Novo Nordisk A/S Distribution transepitheliale de derives de glp-1
WO2001052937A1 (fr) 2000-01-24 2001-07-26 Medtronic Minimed, Inc. Systeme tampon melange pour la stabilisation de preparations pour polypeptides
DK1257577T3 (da) 2000-01-27 2004-08-02 Lilly Co Eli Fremgangsmåde til oplösning af glucagon som peptidforbindelse
EP1396499A3 (fr) 2000-01-27 2004-12-29 Eli Lilly And Company Procédé de solubilisation de composés 1-peptidiques de type glucagon (GLP-1)
US6569901B2 (en) 2000-01-28 2003-05-27 Novo Nordisk A/S Alkynyl-substituted propionic acid derivatives, their preparation and use
US6844321B2 (en) 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue
AU2001248277A1 (en) 2000-04-06 2001-10-23 Novo-Nordisk A/S Shock heat treatment of polypeptides
EA008837B1 (ru) 2000-06-16 2007-08-31 Эли Лилли Энд Компани Аналоги глюкагоноподобного пептида и их применение
JP4798833B2 (ja) 2000-10-24 2011-10-19 一般財団法人化学及血清療法研究所 加熱処理工程を含むヒト血清アルブミンの製造方法
AU2002228608A1 (en) 2000-12-13 2002-06-24 Eli Lilly And Company Amidated glucagon-like peptide-1
EP2186824A3 (fr) 2000-12-13 2010-09-22 Eli Lilly & Company Posologie de traitement chronique à l'aide de peptides insulinotropiques de type glucagon
US20020151467A1 (en) 2000-12-21 2002-10-17 Leung Frank K. Methods and compositions for oral insulin delivery
GB2371227A (en) 2001-01-10 2002-07-24 Grandis Biotech Gmbh Crystallisation - resistant aqueous growth hormone formulations
EA006160B1 (ru) 2001-02-16 2005-10-27 Конджачем, Инк. Долгоживущий глюкагоноподобный пептид 2(glp-2, гпп-2) для лечения желудочно-кишечных заболеваний и расстройств
JP2004518756A (ja) 2001-03-07 2004-06-24 ノボ　ノルディスク　アクティーゼルスカブ Ｇｌｐ−１類似体およびｐｐａｒリガンドの誘導体の組み合わせ使用
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
US20040156835A1 (en) 2001-05-30 2004-08-12 Taiji Imoto Protein preparation
ES2298378T3 (es) * 2001-06-28 2008-05-16 Novo Nordisk A/S Formulacion estable de glp-1 modificado.
CN1335182A (zh) 2001-08-08 2002-02-13 华中科技大学 胰岛素口腔喷剂及其制备工艺
JP2005508895A (ja) 2001-08-28 2005-04-07 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１および基礎インスリンの予備混合物
WO2003035099A1 (fr) 2001-10-19 2003-05-01 Eli Lilly And Company Melanges biphasiques de glp-1 et d'insuline
ATE337014T1 (de) 2002-03-15 2006-09-15 Natimmune As Mannose-bindungsprotein enthaltende pharmazeutische zusammensetzungen
US7273921B2 (en) 2002-09-25 2007-09-25 Novo Nordisk A/S Method for producing acylated peptides
AU2003266216A1 (en) 2002-09-25 2004-04-19 Novo Nordisk A/S Purification process comprising microfiltration at elevated temperatures
WO2004089985A1 (fr) 2003-04-11 2004-10-21 Novo Nordisk A/S Compositions pharmaceutiques stables
EP1631308B1 (fr) 2003-05-30 2013-07-31 Amylin Pharmaceuticals, LLC Nouveaux procedes et nouvelles compositions pour une administration amelioree par voie muqueuse de peptides et de proteines
WO2004105781A2 (fr) 2003-06-03 2004-12-09 Novo Nordisk A/S Compositions pharmaceutiques peptidiques stabilisees
ATE525083T1 (de) 2003-11-13 2011-10-15 Novo Nordisk As Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung
US20060287221A1 (en) 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
JP5558655B2 (ja) * 2003-11-20 2014-07-23 ノヴォ ノルディスク アー／エス 注入デバイスにおける生成および使用に最適なプロピレングリコール含有ペプチド処方
EP2457580A1 (fr) 2004-08-25 2012-05-30 The UAB Research Foundation Activateurs de l'absorption pour l'administration de médicaments
JP5248113B2 (ja) 2004-11-12 2013-07-31 ノヴォ ノルディスク アー／エス ペプチドの安定な処方
US20090325873A1 (en) * 2006-07-18 2009-12-31 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses
UY30820A1 (es) * 2006-12-21 2008-07-03 Centocor Inc Uso de agonistas del receptor de glp-1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652216A (en) * 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
US5869602A (en) * 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6380357B2 (en) * 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
US6384016B1 (en) * 1998-03-13 2002-05-07 Novo Nordisk A/S Stabilized aqueous peptide solutions
US20030220255A1 (en) * 2002-04-04 2003-11-27 Knudsen Liselotte Bjerre GLP-1 agonist and cardiovascular complications

Cited By (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040037818A1 (en) * 1998-07-30 2004-02-26 Brand Stephen J. Treatment for diabetes
US20040209816A1 (en) * 1999-01-29 2004-10-21 Indu Parikh Treatment for diabetes
US20090041731A1 (en) * 1999-01-29 2009-02-12 Indu Parikh Treatment for Diabetes
US8846618B2 (en) 2001-06-28 2014-09-30 Novo Nordisk A/S Stable formulation of modified GLP-1
US20100234299A1 (en) * 2001-06-28 2010-09-16 Novo Nordisk A/S Stable formulation of modified glp-1
US20060093660A1 (en) * 2002-02-27 2006-05-04 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US8277776B2 (en) 2002-02-27 2012-10-02 Pharmain Corporation Compositions for delivery of therapeutics and other materials
US7589169B2 (en) 2002-02-27 2009-09-15 Pharmain Corporation Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US20100158806A1 (en) * 2002-02-27 2010-06-24 Bolotin Elijah M Compositions for Delivery of Therapeutics and Other Materials
US20060239924A1 (en) * 2002-02-27 2006-10-26 Bolotin Elijah M Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
US8231859B2 (en) 2002-02-27 2012-07-31 Pharmain Corporation Compositions for delivery of therapeutics and other materials
US20080015263A1 (en) * 2002-02-27 2008-01-17 Bolotin Elijah M Compositions for delivery of therapeutics and other materials
US8257682B2 (en) 2002-02-27 2012-09-04 Pharmain Corporation Compositions for delivery of therapeutics and other materials
US7790140B2 (en) 2002-02-27 2010-09-07 Pharmain Corporation Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US20100221184A1 (en) * 2002-02-27 2010-09-02 Bolotin Elijah M Compositions for Delivery of Therapeutics and Other Materials
US20060234373A1 (en) * 2002-05-24 2006-10-19 Alex Rabinovitch Treatment for diabetes
US7560425B2 (en) 2002-06-07 2009-07-14 Waratah Pharmaceuticals Inc. Pharmaceutical composition consisting of rapamycine and gastrin 17(LEU15) and a method for treating diabetes
US20040209801A1 (en) * 2002-10-22 2004-10-21 Brand Stephen J. Treatment of diabetes
US20080318865A1 (en) * 2003-06-03 2008-12-25 Novo Nordisk A/S Stabilized Pharmaceutical Peptide Compositions
US8614181B2 (en) 2003-06-03 2013-12-24 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
US8114959B2 (en) 2003-06-03 2012-02-14 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
US20100056451A1 (en) * 2003-06-03 2010-03-04 Novo Nordisk A/S Stabilized Pharmaceutical Peptide Compositions
US20100184687A1 (en) * 2003-08-21 2010-07-22 Novo Nordisk A/S Purification of Glucagon-Like Peptides
US20060211616A1 (en) * 2003-08-21 2006-09-21 Novo Nordisk A/S Purification of glucagon-like peptides
US20100190715A1 (en) * 2003-09-01 2010-07-29 Novo Nordisk A/S Stable Formulations of Peptides
US20060247167A1 (en) * 2003-09-01 2006-11-02 Novo Nordisk A/S Stable formulations of peptides
US8114833B2 (en) 2003-11-20 2012-02-14 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
US20070010424A1 (en) * 2003-11-20 2007-01-11 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US20060074025A1 (en) * 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
US20080318837A1 (en) * 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US20080234200A1 (en) * 2003-12-26 2008-09-25 Nastech Pharmaceutical Company Inc. Method of treatment of a metabolic disease using intranasal administration of exendin peptide
US20090202494A1 (en) * 2004-01-30 2009-08-13 Antonio Cruz Combined use of glp-1 agonists and gastrin for regulating blood glucose levels
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US20080171848A1 (en) * 2004-08-31 2008-07-17 Novo Nordisk A/S Use of Tris(Hydroxymethyl) Aminomethane For the Stabilization of Peptides, Polypeptides and Proteins
US8710181B2 (en) 2004-08-31 2014-04-29 Novo Nordisk A/S Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
US8748376B2 (en) * 2004-11-12 2014-06-10 Novo Nordisk A/S Stable formulations of peptides
US20100173844A1 (en) * 2004-11-12 2010-07-08 Novo Nordisk A/S Stable Formulations of Peptides
US20080318861A1 (en) * 2005-12-08 2008-12-25 Nastech Pharmaceutical Company Inc. Mucosal Delivery of Stabilized Formulations of Exendin
US10507248B2 (en) 2005-12-19 2019-12-17 Pharmain Corporation Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
US9737615B2 (en) 2005-12-19 2017-08-22 PharmalN Corporation Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
US20110207662A1 (en) * 2007-08-03 2011-08-25 Pharmain Corporation Composition for Long-Acting Peptide Analogs
US9657078B2 (en) 2007-08-03 2017-05-23 Pharmain Corporation Composition for long-acting peptide analogs
US8518876B2 (en) 2007-08-03 2013-08-27 PharmalN Corporation Composition for long-acting peptide analogs
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US20090088387A1 (en) * 2007-08-03 2009-04-02 Pharmain Corporation Composition for long-acting peptide analogs
US9090664B2 (en) 2007-08-03 2015-07-28 Pharmain Corporation Composition for long-acting peptide analogs
US20090053169A1 (en) * 2007-08-20 2009-02-26 Pharmain Corporation Oligonucleotide Core Carrier Compositions for Delivery of Nucleic Acid-Containing Therapeutic Agents, Methods of Making and Using the Same
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en) * 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
US9562111B2 (en) 2008-01-09 2017-02-07 Pharmain Corporation Soluble hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
US8999930B2 (en) 2008-01-09 2015-04-07 Pharmain Corporation Soluble hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
US9168288B2 (en) 2010-04-09 2015-10-27 Mount Sinai Hospital Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist
WO2011123943A1 (fr) 2010-04-09 2011-10-13 Mount Sinai Hospital Méthodes de traitement de troubles du tractus gastro-intestinal au moyen d'un agoniste glp-1
US10758592B2 (en) 2012-10-09 2020-09-01 Sanofi Exendin-4 derivatives as dual GLP1/glucagon agonists
US9670261B2 (en) 2012-12-21 2017-06-06 Sanofi Functionalized exendin-4 derivatives
US9745360B2 (en) 2012-12-21 2017-08-29 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/glucagon agonists
US10253079B2 (en) 2012-12-21 2019-04-09 Sanofi Functionalized Exendin-4 derivatives
US9751926B2 (en) 2013-12-13 2017-09-05 Sanofi Dual GLP-1/GIP receptor agonists
US9750788B2 (en) 2013-12-13 2017-09-05 Sanofi Non-acylated exendin-4 peptide analogues
US9789165B2 (en) 2013-12-13 2017-10-17 Sanofi Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists
US9694053B2 (en) 2013-12-13 2017-07-04 Sanofi Dual GLP-1/glucagon receptor agonists
US9775904B2 (en) 2014-04-07 2017-10-03 Sanofi Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
US9771406B2 (en) 2014-04-07 2017-09-26 Sanofi Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4
US9758561B2 (en) 2014-04-07 2017-09-12 Sanofi Dual GLP-1/glucagon receptor agonists derived from exendin-4
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US10806797B2 (en) 2015-06-05 2020-10-20 Sanofi Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate
US9982029B2 (en) 2015-07-10 2018-05-29 Sanofi Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
US11752198B2 (en) 2017-08-24 2023-09-12 Novo Nordisk A/S GLP-1 compositions and uses thereof
US12214017B2 (en) 2017-08-24 2025-02-04 Novo Nordisk A/S GLP-1 compositions and uses thereof
CN112912100A (zh) * 2018-10-26 2021-06-04 诺和诺德股份有限公司 稳定的司美鲁肽组合物及其用途
US11318191B2 (en) 2020-02-18 2022-05-03 Novo Nordisk A/S GLP-1 compositions and uses thereof

Also Published As

Publication number Publication date
ES2298378T3 (es) 2008-05-16
EP1412384B1 (fr) 2007-12-26
US8846618B2 (en) 2014-09-30
JP5562510B2 (ja) 2014-07-30
JP2004535442A (ja) 2004-11-25
US20080167226A1 (en) 2008-07-10
WO2003002136A2 (fr) 2003-01-09
JP2012051894A (ja) 2012-03-15
AU2002316811A1 (en) 2003-03-03
DK1412384T3 (da) 2008-04-28
ATE382057T1 (de) 2008-01-15
EP1412384A2 (fr) 2004-04-28
US20090111752A1 (en) 2009-04-30
DE60224284D1 (de) 2008-02-07
WO2003002136A3 (fr) 2004-03-04
PT1412384E (pt) 2008-03-28
DE60224284T2 (de) 2008-12-18
US20100234299A1 (en) 2010-09-16

Similar Documents

Publication Publication Date Title
US8846618B2 (en) Stable formulation of modified GLP-1
US7632806B2 (en) Stabilized pharmaceutical peptide compositions
US7235627B2 (en) Derivatives of GLP-1 analogs
US8114959B2 (en) Stabilized pharmaceutical peptide compositions
AU2004243531B2 (en) Stabilized pharmaceutical peptide compositions
US20060183682A1 (en) Stabilized pharmaceutical peptide compositions
US7595293B2 (en) Stable pharmaceutical compositions
US6458924B2 (en) Derivatives of GLP-1 analogs
US20090011987A1 (en) Use of Glp-2 for the Treatment of Ischemia-Reperfusion Injury

Legal Events

Date Code Title Description
AS Assignment

Owner name: NOVO NORDISK A/S, DENMARK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FLINK, JAMES M.;LARSEN, SILKE MOLLER;JENSEN, SIMON BJERREGAARD;AND OTHERS;REEL/FRAME:013395/0205;SIGNING DATES FROM 20020829 TO 20020918

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载